Skip to main content

BioCardia, Inc.

corporate_fare Company Profile

BioCardia, Inc.

BCDA·NASDAQ·Life Sciences·CIK 0000925741

We are a clinical-stage company focused on developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Our primary platform is the CardiAMP® autologous mononuclear cell therapy, which is in clinical development for two cardiac conditions: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina due to chronic myocardial ischemia (CMI). This platform targets microvascular dysfunction, aiming to enhance microvascular density and reduce fibrosis. We also have an allogeneic mesenchymal stem cell (MSC) therapy platform, an "off the shelf" cell therapy, in clinical development for ischemic inflammatory HFrEF, based on its immunomodulatory mechanism. While our investigational new drug (IND) for these same cells in acute respiratory distress syndrome has been approved by the FDA, this program has not yet advanced clinically. Our Helix™ transendocardial biotherapeutic delivery system facilitates minimally invasive catheter-based intramyocardial therapeutic delivery for our cardiac candidates. We also partner this delivery platform and offer development services to other companies developing biotherapeutic interventions for local heart delivery. Heart failure, a condition where the heart's blood output is insufficient, affected nearly 6.7 million American adults aged 20 and older in 2024, according to the American Heart Association (AHA). The AHA projects a 55% increase in heart failure prevalence from 2012 to 2030, impacting over 8.5 million people aged 18 and above. The total percentage of the population with HF is projected to rise from 2.4% in 2012 to 3.0% in 2030, with 47% of the effective population estimated to have HFrEF. In 2012, heart failure cost the nation an estimated $30.7 billion.

BioCardia, Inc. (NASDAQ:BCDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for BCDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for BCDA spans 8-K, 10-Q, 4.

Recent high-impact activity:

  • BioCardia Hit With Nasdaq Notice Over $835K Stockholders' Equity vs $2.5M Minimum
  • BioCardia Q3: $2.2M Cash, Going Concern Doubt Beyond January 2027, ATM Exhausted
  • FDA Says Ongoing CardiAMP HF II Trial May Support Approval
  • FDA Finalizes Helix Catheter Meeting Minutes; BioCardia to Submit Follow-On Pre-Submission This Quarter
  • BioCardia Receives Nasdaq Minimum Bid Price Deficiency Notice

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$8.23M
Op. Cash Flow
-$7.44M
Free Cash Flow
-$7.44M
Operating Income
-$8.28M
Cash & Equivalents
$2.5M
Debt / Equity
0.00×
Shares Outstanding
10.76M sh
Source: 10-K · filed 2026-03-24 · accession 0001437749-26-009587

Short Interest & Short Volume

6.29 days to cover

FINRA reported short interest of 735,104 shares in BCDA as of the October 30, 2026 settlement, a 8.4% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 66.9% of BCDA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)735,104 shares as of October 30, 2026
Change vs prior period▲ 8.4%
Days to cover6.29 at avg daily volume of 116,810
Daily short volume (FINRA facilities)66.9% of 159,406 shares on November 20, 2026
5-day average short volume62.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for BCDA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-12.

ATM program

Cash Runway Extended · ATM Program Exhausted

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$0.75 -4.46% today
52-week range · as of 2026-11-20 $0.661 – $1.8
Market cap
$11.88M
Volume
352.4K (2.9× avg)
3-mo avg 120.9K
Live data · 2026-11-22 03:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BCDA - Latest Insights

BCDA
Nov 20, 2026, 4:31 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.785
Real-time Price: $0.750 info
Change: -$0.035 (-4%) info
Market Cap: $11.884M info
BCDA
Nov 12, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.831
Real-time Price: $0.750 info
Change: -$0.081 (-10%) info
Market Cap: $11.884M info
BCDA
Oct 07, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.750 info
Change: -$0.3461 (-32%) info
Market Cap: $11.884M info
BCDA
Aug 24, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.980
Real-time Price: $0.750 info
Change: -$0.230 (-23%) info
Market Cap: $11.884M info
BCDA
Aug 21, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.750 info
Change: -$0.260 (-26%) info
Market Cap: $11.884M info
BCDA
Aug 12, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.902
Real-time Price: $0.750 info
Change: -$0.152 (-17%) info
Market Cap: $11.884M info
BCDA
Aug 12, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.870
Real-time Price: $0.750 info
Change: -$0.120 (-14%) info
Market Cap: $11.884M info
BCDA
Jun 24, 2026, 6:16 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.750 info
Change: -$0.320 (-30%) info
Market Cap: $11.884M info
BCDA
Jun 18, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.750 info
Change: -$0.190 (-20%) info
Market Cap: $11.884M info
BCDA
Jun 12, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7992
Real-time Price: $0.750 info
Change: -$0.0492 (-6%) info
Market Cap: $11.884M info
BCDA
Jun 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.880
Real-time Price: $0.750 info
Change: -$0.130 (-15%) info
Market Cap: $11.884M info
BCDA
Jun 05, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.37
Real-time Price: $0.750 info
Change: -$0.620 (-45%) info
Market Cap: $11.884M info
BCDA
Jun 05, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8889
Real-time Price: $0.750 info
Change: -$0.1389 (-16%) info
Market Cap: $11.884M info
BCDA
May 28, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.9422
Real-time Price: $0.750 info
Change: -$0.1922 (-20%) info
Market Cap: $11.884M info
BCDA
May 28, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.750 info
Change: -$0.140 (-16%) info
Market Cap: $11.884M info
BCDA
May 21, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.9785
Real-time Price: $0.750 info
Change: -$0.2285 (-23%) info
Market Cap: $11.884M info
BCDA
May 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.9215
Real-time Price: $0.750 info
Change: -$0.1715 (-19%) info
Market Cap: $11.884M info
BCDA
May 15, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.10
Real-time Price: $0.750 info
Change: -$0.350 (-32%) info
Market Cap: $11.884M info
BCDA
May 15, 2026, 8:05 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.10
Real-time Price: $0.750 info
Change: -$0.350 (-32%) info
Market Cap: $11.884M info
BCDA
May 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $0.750 info
Change: -$0.410 (-35%) info
Market Cap: $11.884M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets